UroGen Pharma Ltd
URGNHealthcare|Biotechnology|USA
$38.57
-1.67 (-4.15%)
Upcoming Data Readouts (1)
Mar 2027
Est. completion
P3Upper Urinary Tract Urothelial Carcinoma
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131n=70
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2025
P3
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Apr 2023
P3
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550